Zacks Investment Research
12 Oct 2026, 16:51 UTC · 1h ago
BMY Surges 35.7% in a Year: Should You Buy, Sell or Hold the Stock?
Impact · against what's priced in
The article provides no new catalysts for BMY or MRK, as the growth metrics and product milestones mentioned are already reflected in the recent share price rallies. For MRK, the mention of Reblozyl's growth is negligible given the stock's current focus on Keytruda's long-term trajectory.
- MRK+0.00
Already priced in
- The price assumes
A steady continuation of Keytruda's current revenue, which already drives the bulk of the company's $58 billion pharmaceutical segment.
The article mentions Reblozyl as a growth driver, but the current price already assumes steady pharmaceutical revenue and focuses on the larger Keytruda patent cliff and vaccine upside.
What MRK's price assumes · Sep 11
Search tags
